CA3260047A1 - KRAS G12C INHIBITOR FOR CANCER TREATMENT - Google Patents
KRAS G12C INHIBITOR FOR CANCER TREATMENTInfo
- Publication number
- CA3260047A1 CA3260047A1 CA3260047A CA3260047A CA3260047A1 CA 3260047 A1 CA3260047 A1 CA 3260047A1 CA 3260047 A CA3260047 A CA 3260047A CA 3260047 A CA3260047 A CA 3260047A CA 3260047 A1 CA3260047 A1 CA 3260047A1
- Authority
- CA
- Canada
- Prior art keywords
- kras
- dose
- pharmaceutically acceptable
- acceptable salt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263357227P | 2022-06-30 | 2022-06-30 | |
| US63/357,227 | 2022-06-30 | ||
| US202363486785P | 2023-02-24 | 2023-02-24 | |
| US63/486,785 | 2023-02-24 | ||
| US202363496447P | 2023-04-17 | 2023-04-17 | |
| US63/496,447 | 2023-04-17 | ||
| PCT/US2023/026554 WO2024006424A1 (en) | 2022-06-30 | 2023-06-29 | Kras g12c inhibitor for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3260047A1 true CA3260047A1 (en) | 2024-01-04 |
Family
ID=87468549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3260047A Pending CA3260047A1 (en) | 2022-06-30 | 2023-06-29 | KRAS G12C INHIBITOR FOR CANCER TREATMENT |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240108618A1 (https=) |
| EP (1) | EP4547251A1 (https=) |
| JP (2) | JP7496917B2 (https=) |
| KR (1) | KR20250027777A (https=) |
| CN (1) | CN119907671A (https=) |
| CA (1) | CA3260047A1 (https=) |
| IL (1) | IL317823A (https=) |
| MA (1) | MA71325A (https=) |
| MX (1) | MX2025000105A (https=) |
| WO (1) | WO2024006424A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| ES2929700T3 (es) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | Inhibidores de KRas g12c |
| BR112022022021A2 (pt) * | 2020-04-30 | 2022-12-13 | Genentech Inc | Anticorpos, ácido(s) nucleico(s), vetor, célula hospedeira, processo para produzir um anticorpo, métodos para rastrear um anticorpo, detectar kras-gdp, obter um inibidor, detectar a alquilação de kras, tratar um câncer, rastrear compostos, medir a ligação de uma proteína e medir o engajamento do alvo de um inibidor, kit, chaperona de cristalização, método de cristalização e superfície de biossensor |
| US20230285498A1 (en) * | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
| MX2023003060A (es) * | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| EP4486345A1 (en) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
-
2023
- 2023-06-29 EP EP23745331.1A patent/EP4547251A1/en active Pending
- 2023-06-29 KR KR1020257002609A patent/KR20250027777A/ko active Pending
- 2023-06-29 IL IL317823A patent/IL317823A/en unknown
- 2023-06-29 CN CN202380063188.1A patent/CN119907671A/zh active Pending
- 2023-06-29 US US18/344,134 patent/US20240108618A1/en active Pending
- 2023-06-29 WO PCT/US2023/026554 patent/WO2024006424A1/en not_active Ceased
- 2023-06-29 CA CA3260047A patent/CA3260047A1/en active Pending
- 2023-06-29 MA MA71325A patent/MA71325A/fr unknown
- 2023-06-30 JP JP2023108177A patent/JP7496917B2/ja active Active
-
2024
- 2024-05-28 JP JP2024086236A patent/JP2024112968A/ja active Pending
-
2025
- 2025-01-06 MX MX2025000105A patent/MX2025000105A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA71325A (fr) | 2025-04-30 |
| JP7496917B2 (ja) | 2024-06-07 |
| CN119907671A (zh) | 2025-04-29 |
| US20240108618A1 (en) | 2024-04-04 |
| AU2023297941A1 (en) | 2025-01-16 |
| MX2025000105A (es) | 2025-02-10 |
| JP2024007504A (ja) | 2024-01-18 |
| KR20250027777A (ko) | 2025-02-27 |
| WO2024006424A1 (en) | 2024-01-04 |
| JP2024112968A (ja) | 2024-08-21 |
| IL317823A (en) | 2025-02-01 |
| TW202421145A (zh) | 2024-06-01 |
| EP4547251A1 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240108618A1 (en) | Kras g12c inhibitor dosing regimens | |
| EP3923941B1 (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| JP7668777B2 (ja) | 癌治療 | |
| TWI685341B (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| WO2018201016A1 (en) | Treatment of her2 positive cancers | |
| US12213958B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| CN103582479A (zh) | 用pi3k抑制剂化合物治疗间皮瘤的方法 | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| AU2021281336A1 (en) | Methods of treating HER2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy | |
| EP4580626A1 (en) | Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer | |
| EP4159238A1 (en) | Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| AU2023297941B2 (en) | Kras g12c inhibitor for treating cancer | |
| TWI921668B (zh) | Kras g12c抑制劑之給藥方案 | |
| JP2024514112A (ja) | ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 | |
| US12611403B2 (en) | Combined pharmaceutical composition of c-Met kinase inhibitor and anti-PD-L1 antibody | |
| Yoshimura et al. | Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer | |
| CN114667159A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| Chen et al. | Preclinical activity of the rational combination of apatinib in combination with CPT-11 in KRAS-mutant colorectal cancer patient-derived xenograft model | |
| HK40094176A (zh) | 用於治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物 | |
| HK40072142A (en) | Quinoline derivative used for combination treatment of small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241219 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250324 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250324 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |